Compare ADMA Biologics Inc (ADMA) vs Genuine Parts Company (GPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Genuine Parts Company — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Genuine Parts Company trades at $124.94 (market cap $17.71B). The key difference: Genuine Parts Company is far larger — about 8.3× ADMA Biologics Inc's market cap, and Genuine Parts Company pays a 3.3% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | GPC | |
|---|---|---|
Market Cap | $2.13B | $17.71B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $149.26 |
52-Week Low | $7.60 | $92.47 |
Enterprise Value | $2.20B | $23.92B |
Dividend Yield | — | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
GPC trades at $128.67, down 2.94% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed earnings, missing in Q3 and Q4 2025 but beating in Q1 2026, with Q2 2026 results due July 21, 2026. Financials show revenue growth to $24.3B in 2025 but a sharp decline in net income margin to 0.24%, while the P/E ratio of 292.41 reflects high valuation relative to earnings. A dividend of $1.06 per share is scheduled for payment on July 2, 2026.
The outlook is cautious due to weak profitability and high P/E, but analyst consensus is a Buy with a $133 price target, suggesting modest upside. Risks include earnings volatility and competitive pressures in the automotive parts sector. The stock's near-term direction hinges on Q2 2026 earnings, with support at $126 and resistance at $131.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
